Failure of the ubiquitin proteasome system in Parkinson's disease

Nature Reviews Neuroscience

Volumn 2, Issue 8, 2001, Pages 589-594

  McNaught, Kevin St P ^a,b   Olanow, C Warren ^b   Halliwell, Barry ^c   Isacson, Ole ^a   Jenner, Peter ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; MULTIENZYME COMPLEX; NERVE PROTEIN; PEPTIDE HYDROLASE; PROTEASOME; UBIQUITIN;

ANIMAL; GENETICS; HUMAN; LEWY BODY; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; CYSTEINE ENDOPEPTIDASES; HUMANS; LEWY BODIES; MULTIENZYME COMPLEXES; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA; UBIQUITINS;

EID: 0035430788     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/35086067     Document Type: Article

References (66)

1. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272 (1996).
2. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nature Rev. Neurosci. 2, 492-501 (2001).
3. Schapira, A. H. et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145 (1990).
4. Sian, J. et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355 (1994).
5. Dexter, D. T. Alterations in the levels of iron, ferritin and other trace met als in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975 (1991).
6. McNaught, K. S., Lee, M.-H., Hyun, D.-H. & Jenner, P. in Parkinson's Disease, Advances in Neurology (eds Calne, D. B. & Calne, S. M.) 73-82 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
7. Halliwell, B. & Jenner, P. Impaired clearance of oxidised proteins in neurodegenerative diseases. Lancet 351, 1510 (1998).
8. Alam, Z. I. et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329 (1997).
9. Lopiano, L. et al. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem. Int. 37, 331-336 (2000).
10. McNaught, K. S. & Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194 (2001).
11. Sherman, M. Y. & Goldberg, A. L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32 (2001).
12. Pickart, C. M. Ubiquitin in chains. Trends Blochem. Sci. 25, 544-548 (2000).
13. DeMartino, G. N. & Slaughter, C. A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274, 22123-22126 (1999).
14. Pollanen, M. S., Dickson, D. W. & Bergeron, C. Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol. 52, 183-191 (1993).
15. Golbe, L. I., Di lorio, G., Bonavita, V., Miller, D. C. & Duvoisin, R. C. A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 27, 276-282 (1990).
16. Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J. & Nicholson, G. A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr a- synuclein mutation. Ann. Neurol. 49, 313-319 (2001).
17. Shashidharan, P. et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 877, 379-381 (2000).
18. Shimura, H. et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668-672 (1999).
19. Shimura, H. et al. Ubiquitination of a new form of a- synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269 (2001).
20. Lowe, J., McDermott, H., Landon, M., Mayer, R. J. & Wilkinson, K. D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161, 153-160 (1990).
21. Ii, K., Ito, H., Tanaka, K. & Hirano, A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125-131 (1997).
22. Good, P F., Hsu, A., Werner, P, Perl, D. P & Olanow, C. W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342 (1998).
23. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
24. Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290, 985-989 (2000).
25. Johnston, J. A., Ward, C. L. & Kopito, R. R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143, 1883-98 (1998).
26. Wigley, W. C. et al. Dynamic association of proteasomal machinery with the centrosome. J. Cell Biol. 145, 481-490 (1999).
27. Kopito, R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530 (2000).
28. Davies, K. J. Degradation of oxidized proteins by the 20S proteasome. Blochlmle 83, 301-310 (2001).
29. Masliah, E. et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
30. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000).
31. Hattori, N. et al. Autosomal recessive juvenile parkinsonism: a key to understanding nigral degeneration in sporadic Parkinson's disease. Neuropathology 20, S85-90 (2000).
32. Cummings, C. J. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
33. De Silva, H. R., Khan, N. L. & Wood, N. W. The genetics of Parkinson's disease. Curr. Opin. Genet. Dev. 10, 292-298 (2000).
34. Polymeropoulos, M. H. et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197-1199 (1996).
35. Polymeropoulos, M. H. et al. Mutation in the a- synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
36. Kruger, R. et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nature Genet. 18, 106-108 (1998).
37. Vaughan, J. et al. The a-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. Ann. Neurol. 44, 270-273 (1998).
38. Solano, S. M., Miller, D. W., Augood, S. J., Young, A. B. & Penney, J. B. Jr Expression of a-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol. 47, 201-210 (2000).
39. Kanda, S., Bishop, J. F., Eglitis, M. A., Yang, Y. & Mouradian, M. M. Enhanced vulnerability to oxidative stress by a-synuclein mutations and C-terminal truncation. Neuroscience 97, 279-284 (2000).
40. Lee, M., Hyun, D., Halliwell, B. & Jenner, P. Effect of the overexpression of wild-type or mutant a-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009 (2001).
41. Zhou, W., Hurlbert, M. S., Schaack, J., Prasad, K. N. & Freed, C. R. Overexpression of human a-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33-43 (2000).
42. Borden, K. L. Structure/function in neuroprotection and apoptosis. Ann. Neurol. 44, S65-71 (1998).
43. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant a- synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318-1320 (1998).
44. Weinreb, P H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P T. Jr NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715 (1996).
45. Bennett, M. C. et al. Degradation of a-synuclein by proteasome. J. Biol. Chem. 274, 33855-33858 (1999).
46. Ghee, M., Fournier, A. & Mallet, J. Rat a-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75, 2221-2224 (2000).
47. Tanaka, Y. et al. Inducible expression of mutant a- synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926 (2001).
48. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
49. Wintermeyer, P et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 11, 2079-2082 (2000).
50. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nature Genet. 23, 47-51 (1999).
51. Ishikawa, A. & Takahashi, H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J. Neurol. 245, 4-9 (1998).
52. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
53. Lucking, C. B. et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342, 1560-1567 (2000).
54. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
55. Imai, Y. et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105, 891-902 (2001).
56. Zhang, Y. et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359 (2000).
57. Yoritaka, A. et al. Immunohistochemical detection of 4- hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 2696-2701 (1996).
58. Jenner, P. & Olanow, C. W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72-84 (1998).
59. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000).
60. Nam, S., Smith, D. M. & Dou, Q. P. Ester bond- containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 276, 13322-13330 (2001).
61. Lee, M., Hyun, D. H., Jenner, P & Halliwell, B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J. Neurochem. 78, 32-41 (2001).
62. Tatton, N. A., Maclean-Fraser, A., Tatton, W. G., Perl, D. P. & Olanow, C. W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 44, S142-148 (1998).
63. Keller, J. N., Huang, F. F. & Markesbery, W. R. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149-156 (2000).
64. Gaczynska, M., Osmulski, P. A. & Ward, W. F. Caretaker or undertaker? The role of the proteasome in aging. Mech. Ageing Dev.122, 235-254 (2001).
65. Gibb, W. R. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurq. Psychiatry 51, 745-752 (1988).
66. McCutchen-Maloney, S. L. et al. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J. Biol. Chem. 275, 18557-18565 (2000).